Arvinas After Collaboration Shifts: PROTAC Platform Leverage, Partner Reliance, and the Next Phase of Value Creation

Arvinas, Inc. stands at a pivotal juncture as it doubles down on a biotech model defined by platform innovation and strategic out-licensing. With its PROTAC technology at the core, the company’s near-term commercial prospects and risk profile have shifted following the transfer of VEPPANU commercialization rights to Rigel and the global development of luxdegalutamide by Novartis. While Arvinas reports a substantial liquidity position, the company’s future value will increasingly be determined by the execution of its partners and its ability to secure new licensing deals for pipeline assets. This transition highlights both the scalability of the PROTAC platform and the operational and strategic vulnerabilities inherent in a partner-dependent approach. [S2] [N2]

Recent Partner Realignment Reshapes Commercialization and Revenue Streams

Arvinas’s most material developments in 2026 are the out-licensing of VEPPANU’s global rights to Rigel and the continued global development of luxdegalutamide (ARV-766) by Novartis. Rigel now holds exclusive responsibility for VEPPANU’s development, manufacturing, and commercialization, with Arvinas entitled to a share of sublicensing revenues. Meanwhile, collaborations with Pfizer and Genentech have ended, removing two large pharma partners from Arvinas’s collaborative roster. These shifts concentrate Arvinas’s near-term commercial exposure with Rigel and Novartis, increasing dependency on their execution and commercial priorities. [S2] [N2] [N3]

How the PROTAC Model Translates Innovation into Cash Flow

Arvinas’s business model is built around the monetization of its proprietary PROTAC protein degrader technology through partnerships, out-licensing, and milestone/royalty streams. The company’s economics are characterized by high upfront and milestone payments from partners, potential royalties and sublicensing revenue, and limited direct commercial infrastructure investment. This model minimizes fixed costs associated with manufacturing and sales but exposes Arvinas to variable and lumpy revenue recognition, often tied to partner-dependent milestones or regulatory events.

With no owned manufacturing, Arvinas’s cost structure is dominated by R&D spending and third-party service payments to CROs and CMOs. Operating leverage is primarily achieved through successful out-licensing of pipeline assets, as demonstrated by the VEPPANU and luxdegalutamide deals. However, the company’s P&L remains structurally negative in the absence of significant recurring royalty income or product launches under its own label.

The model is scalable if more partners are secured, but also exposes Arvinas to periods of low cash inflow if licensing activity stalls.

The variable nature of Arvinas’s revenue streams also introduces challenges in financial forecasting and capital allocation. Because milestone payments and royalties depend on partner achievements, the timing and magnitude of cash inflows can be unpredictable, complicating budgeting for R&D investments and operational expenses. This uncertainty necessitates a conservative approach to spending and a strong emphasis on maintaining liquidity buffers. Furthermore, the absence of direct commercial operations means that Arvinas must rely heavily on its business development team to continuously identify and negotiate new partnerships, making deal flow a critical driver of sustainable cash generation.

PROTAC Platform Offers Differentiation, But Partner Reliance Limits Defensibility

Arvinas’s competitive position is anchored by its first-mover status and intellectual property in targeted protein degradation, a modality that enables the elimination of disease-driving proteins previously considered ‘undruggable.’ This gives Arvinas a scientific and platform advantage, especially as the PROTAC field matures. However, the competitive moat is partly eroded by the company’s reliance on external partners for downstream development, regulatory strategy, and commercialization.

Relevant competitor categories include both large pharmaceutical companies with internal protein degradation programs and other biotech firms advancing next-generation degrader platforms. Larger competitors may have direct access to global commercial infrastructure, deeper pipelines, and greater ability to absorb R&D failure or regulatory setbacks.

Arvinas’s economics and negotiating leverage are strongest when its platform generates assets that are highly sought after by partners. However, as the field evolves and competitors close the technology gap, the terms of future partnerships may become less favorable, and the risk of pipeline overlap or competitive displacement rises.

The reliance on partners for downstream activities also constrains Arvinas’s ability to influence market positioning and competitive responses. While the PROTAC platform provides a technological edge, the ultimate success of partnered assets depends on how effectively collaborators execute clinical development, regulatory strategy, and commercialization. This dynamic can limit Arvinas’s input in critical decisions that shape product differentiation and market access strategies, potentially affecting competitive outcomes. Additionally, as more players enter the targeted protein degradation space, the risk of overlapping indications and intellectual property disputes may increase, requiring vigilant portfolio management and strategic collaboration structuring.

If Partners Execute, Royalty Streams and New Deals Could Drive a Flywheel Effect

The most favorable outcome for Arvinas is a scenario in which Rigel successfully commercializes VEPPANU in the U.S. and globally, and Novartis advances luxdegalutamide through late-stage trials and into the market. This would validate the PROTAC platform’s commercial viability and generate royalty and milestone payments that could, in turn, fund further pipeline development or attract new partners.

A reinforcing flywheel could emerge if Arvinas secures additional out-licensing agreements—such as for ARV-806—demonstrating the platform’s breadth and generating non-dilutive capital. Confirmation would come from public disclosures of new licensing deals, substantial milestone receipts, or the initiation of commercial sales by partners. Falsification would be evident if VEPPANU or luxdegalutamide programs stall, are deprioritized, or fail to generate meaningful commercial traction.

Execution Now Hinges on Partner Timelines and Licensing Cadence

The most plausible scenario is one in which Arvinas remains fundamentally a platform innovator and deal-maker, with near-term revenue and value realization tied to the pace of partner development and the cadence of new out-licensing. The company continues to operate at a net loss, with its reported liquidity position, while awaiting key clinical or regulatory milestones from Rigel and Novartis.

Incremental upside could come from new out-licensing deals, but the company’s ability to control timelines and commercial priorities is limited. Evidence for this scenario includes steady but lumpy revenue recognition, continued R&D expense, and public statements about ongoing business development efforts. A shift away from this scenario would be signaled by either a major partner setback or, alternatively, a transformative internal or co-commercialization move.

If Partner Underperformance or Termination Occurs, Value Realization Could Stall

In a less favorable scenario, Rigel or Novartis underperform in their development or commercialization efforts, delay programs, or terminate agreements. This would leave Arvinas without near-term commercial milestones or royalty streams and could force the company to seek additional capital or attempt to reclaim and relaunch assets at significant cost and risk.

Additional downside could stem from increased competition in the PROTAC space, eroding Arvinas’s negotiating leverage for future deals or leading to pipeline redundancy. Confirmation of this scenario would include delays or terminations disclosed by partners, a lack of new out-licensing activity, or a material increase in cash burn without offsetting revenue inflow.

Milestones That Will Shape Arvinas’s Platform Value and Partner-Driven Trajectory

Progress updates from Rigel on VEPPANU clinical development, regulatory submissions, and commercialization milestones.

Disclosures from Novartis regarding the advancement, clinical trial status, or commercialization plans for luxdegalutamide (ARV-766).

Announcements of new out-licensing agreements or business development deals for pipeline assets such as ARV-806.

Evidence of milestone or royalty payments received from existing partners, including timing and magnitude (if disclosed).

Updates on the company’s cash burn rate, R&D expense trends, and changes in liquidity position.

Any material changes in the competitive landscape of targeted protein degradation, such as major clinical readouts or new entrants.

Operational or regulatory issues with third-party CROs, CMOs, or supply chain partners that could impact clinical or commercial timelines.

Public disclosures regarding the pursuit of internal versus partnered product commercialization, which would signal a strategic shift.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.